Insulin (human) recombinant
Biological ActivityEndogenous insulin receptor agonist (Ki = 4.85 nM). Decreases plasma glucose levels, proteolysis, lipolysis and gluconeogenesis and increases glycogen and fatty acid synthesis in vivo.
(Modifications: Disulfide bridge between 6 - 11, 7 -7*, 20 - 19*)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Leney and Tavare (2009) The molecular basis of insulin-stimulated glucose uptake: signalling, trafficking and potential drug targets. J.Endocrinol. 203 1. PMID: 19389739.
Ou et al (2001) The binding characteristics of insulin-MTX to insulin receptor. Hua.Xi.Yi.Ke.Da.Xue.Xue.Bao. 32 538. PMID: 12528542.
Torlinska et al (2000) Age dependent changes of insulin receptors in rat tissues. J.Physiol.Pharmacol. 51 871. PMID: 11220495.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Insulin (human) recombinant
expressed in yeast from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Insulin (human) recombinant, expressed in yeast, supplier, Endogenous, peptide, agonists, IGF, Receptors, nsulin-like, Receptor, Tyrosine, Kinases, RTKs, Tocris Bioscience, Insulin and Insulin-like Receptors Activator products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.